Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Greekman - post 187 very true, however lets not forget the NHS need to spend on eliminating MRSA first. Something CardioQ doesn't protect against.

I held these shares for some time before selling due to lack of confidence in the board to actully land sales. I do hope that one day they will come and like many I believe in CardioQ... Although Delex has many probally hundreds of medical reports backing CardioQ publicity focus continues to be in the wrong areas. Deltex and investors should target the press and media with CardioQ to build pressure on both the NHS and government to fund this ever needed technology.. The more people that know about CardioQ the better chance Deltex has of selling its product before its patient expires and cheap copies are launched into the market!

Just in.

Yet another example of cost savings that can be made.
Cost savings, taking into account the cost of the
Deltex Medical probe and the reduction in whole blood, blood products and
ancillary equipment used, but excluding savings from length of stay reduction,
were approximately 3,500 per patient.
'There are approximately 80,000 patients every year in Europe alone who could
benefit enormously from this approach if it were adopted as a standard of care,
and there is the additional potential for substantial cost savings at
hospitals.'
That's 280 million euro's. When will the powers that be wake up to this fantastic product.

When they stop investing in endless layers of middle management.

sd

Results out, showing a steady but sure progress.
Looking forward the future does look very promising. As has been mentioned many times with the CardioQ, once this really does gather momentum, there will be no stopping it. All IMHO of course.

yep.. steady as she goes.....still one for the long term.. I'll continue to hold and will look to top up when SP falls below 18p. imho SP is bound to drift down during quiet periods..

Very true skyhigh, hope your also keeping an eye on Deltex's patients.... Expirey etc... Its also worth doing some research on other companies that have medical technology to offer and am having difficulty like Deltex selling their product.... Having said this you could always take matters into your own hands and run a special sponsored "whatever" to raise money to buy your local hospital a CardioQ!!....... Just a thought.

Re the RNS

Looking good. It appears the dam has finally started to break. Don't mind a share placing at all as the proceeds are for all the right reasons. It's a light placing percentage wise anyway.
All indications for the next 6 to 12 months look to increasing, sales of the monitors and probes.

I like the increase in U.K. monitor sales announced at the AGM a few days ago. It was something like 34 monitors in the U.K. in the whole of 2005. Now they say they've already had 24 U.K. sales in 2006, so if that covers 4 months, that suggests 72 monitors will be sold for the whole of 2006. That's more than double last year! Even being pessimistic, they have almost made 70% of last year's U.K. monitor sales in the first 4 months of this year, so they should comfortably exceed last year's sales.

I miagine that NICE approval has had something to do with this.

Just released.
A glimmer of hope in what is a very bad week over all...

LONDON (AFX) - Deltex Medical Group PLC said an audit conducted at the Royal Alexandria Hospital in Paisley found that patients subject to haemodynamic optimisation using its CardioQ device had a mean length of stay in hospital of 9.55 days compared to 12 days for those patients that had received a standardised anaesthetic.

Dr David Alcorn, who has been in charge of auditing the procedure at the hospital, said: 'We are greatly encouraged by the results achieved. This has major benefits not only for patients but for clinicians and hospitals throughout the country.'

Deltex Medical's Chief Executive, Andy Hill, said: 'The evidence from this audit comprises further validation of the clinical and cost effectiveness of the CardioQ.'

Nothing new this, lost count how many times similar reports and statements have been made. If Deltex received as many orders as it did proff CardioQ works reports I'd have been rich a long time ago!!

True, just clutching at straws I guess... :-(

Skyhigh,

Just got in and saw the AFX. It makes you wonder what the NHS is waiting for, but it also goes to show how pathetic the NHS managers are. This is the problem with the NHS through and through, they won't spend 1 today to save 2 tomorrow. I'm sure the orders will come eventually ( from the NHS ) but I am even more convinced that the CardioQ will be rolled out across the USA well before they are in general use here.

Shows how pathetic this government is as well.. They should be driving through reforms and better healthcare practices that also make better use of funds... still as said it's... good news.!.

Mr John Christou recently purchased 500,000 shares. It appears someone has faith. Anyone know who he is.

No idea, doesn't appear to be on the board of directors @ DEMG.
2517

THE COUNT--->ALL

I made this post over on the dark side a little earlier if it helps.


Post as follows....

The Count - 19 May'06 - 10:29 - 450 of 474

THE COUNT--->ALL

Ok, I have had clarification from the company about the ill advised timing of yesterday's RNS.

I copy some of the email below.

To clarify a couple of points:

- this was an RNS REACH announcement, rather than RNS
- broker advice was that there was nothing new about this (i.e. we already know CardioQ good for patients & reduces stay) therefore REACH
- timing driven by an article appearing in the Edinburgh Evening Times yesterday evening (link below) and in anticipation of attached article from The Scotsman today; there was also coverage on BBC radio Scotland yesterday
- the whole point of this exercise is to unblock the sales pipeline in Scotland; doing that would/will generate a stream of strong RNS news
- the announcement was therefore timed to prevent any criticism if Scotsman readers made the link & started driving the price when other market participants did not have access to the same story
- NB the September 2004 Times article re the Medway was not printed in Scottish edition and was of limited value to us there; today's feature re-balances this.

Link to the article as follows....



Now, on reading that article, things do start to look very interesting indeed. I particularly like the '1m patients a year' reference.....errr, that's just here in the UK alone incidentally.

Let's do some basic sums to unearth the sort of potential we could be looking at here. 1m probes pa at 60 per probe gives us probe revenue of circa 60m pa. Now, conservatively speaking, at least 50% (should be a lot more) should flow through to the bottom line. So we are talking about potentially, 30m plus profits pa....IN THE UK alone!!!!! And we are currently trading on a market cap of only 14m.

Replicate this in other major economies around the world and the potential is absolutely staggering.

In case people want to go out and start buying this like there was no tomorrow (which I very much doubt at this point), this is still mainly about potential. We are currently the market leader in the UK and need to remain there to get a decent slug of this potential. We are dealing with highly bureaucratic, administrative and labour intensive nightmares when dealing with health services of all ilks.

The biggest task/hurdle though, and one we are rapidly overcoming, is persuading highly conservative and critical medical professionals (the doctors, surgeons, intensivists or whatever you wish to call them) of the benefits to their patients and to those that hold the purse strings of this technology. Of course, there will always be sceptics too, but the numbers of the 'converted' are slowly beginning to speak for themselves too and this is growing. And despite this growth, actual usage still lags current clinical demand by a factor of 10.

The dam is cracking....one day we hope it will break.

But the potential is all out there. Despite this being a slow process, I am as excited as ever about this company and this technology.

Regards,

THE COUNT!

PS. Here are another couple of links to go with the above.


www.eveningtimes.co.uk/hi/news/5052443.html

http://news.bbc.co.uk/1/hi/scotland/glasgow_and_west/4992140.stm

Good summing up. Cheers.

And the way the NHS see it is 60 extra per patient per probe, add this to the already troubled budget and Mr Gordon Brown isn't a happy bunny.

Currently the NHS do not want to process more patients than they are doing as it costs more money. If and when local GPs start taking some of the strain off the NHS they may have room for investment or further admin staff! As I've said before Deltex is one company waiting for its order books to fill, there are many others.

I agree that the NHS do not want to process more patients, and that is how I looked at the situation, but they have to show they are treating patients efficiently, ie cost effective. The problem is the more incompetent the management show they are, they employ even more managers to sort the mess out. But with many operations now being farmed out to private hospitals, keeping the cost down in these units is important as they are vying for each patient. Competition will win the day.

Greekman - You are correct competition will win the day. However I don't recall the private sector such as Bupa ever placing an order with Deltex. Now surely you'd expect adoption in the private sector before in the public!!